|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As discussed earlier, Johnson & Johnson reported a 12.6% increase in revenues to $20.0 million in 1Q18 as compared to $17.8 million in 1Q17. The increase included 8.4% growth in revenues at constant exchange rates and a 4.2% positive impact of foreign exchange.
Bristol-Myers Squibb (BMY) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues in 1Q18. It reported EPS of $0.94 on revenues of $5.2 billion in 1Q18 today, compared to analysts’ estimates for EPS of $0.85 on revenues of $5.2 billion.
The Somerset, N.J., company that Endo is buying specializes in sterile injectable products. The deal also include a manufacturing facility in India.
As discussed earlier, Johnson & Johnson (JNJ) reported revenue growth of 12.6% in its 1Q18 revenues to $20.0 billion.
DUBLIN, April 26, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics' contract developer and manufacturer. Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial and pipeline products as well as Wintac's manufacturing capabilities for those products.
In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.
As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.
GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.
Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.
In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.
Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.
Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.
As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.
Gilead Sciences (GILD) is currently studying a combination of anti-MMP-9 (anti-matrix metalloproteinase-9) antibody andecaliximab with modified FOLFOX 6 in a Phase 3 trial as a therapy for treatment-naïve advanced gastric or GAMMA-1 (gastroesophageal junction adenocarcinoma) patients. The company also expects to conclude its Phase 2 trial comparing an andecaliximab-nivolumab combination with a nivolumab monotherapy in gastric cancer in 2018. If these trials prove successful, Gilead Sciences could emerge as major competition for other gastric cancer therapy players such as Eli Lilly (LLY) and Roche (RHHBY).
On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.
Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.
- Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address ...
Eli Lilly & Co. has attracted interest from private equity firms including Bain Capital and Advent International Corp. for its animal-health business, as the pharmaceutical giant considers options for ...
In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.
Eli Lilly topped the Street's first-quarter estimates Tuesday on unexpected strength from two diabetes drugs and the early impact of a chemotherapy tie with Dow Jones' component Merck.
In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.